These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1024 related articles for article (PubMed ID: 31883150)
1. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. Gagelmann N; Ayuk F; Atanackovic D; Kröger N Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596 [No Abstract] [Full Text] [Related]
3. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q Front Immunol; 2021; 12():720571. PubMed ID: 34421924 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681 [TBL] [Abstract][Full Text] [Related]
5. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333 [TBL] [Abstract][Full Text] [Related]
6. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997 [TBL] [Abstract][Full Text] [Related]
7. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J Front Immunol; 2021; 12():755866. PubMed ID: 34777368 [TBL] [Abstract][Full Text] [Related]
8. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013 [TBL] [Abstract][Full Text] [Related]
9. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma]. Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066 [No Abstract] [Full Text] [Related]
10. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302 [TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ma T; Shi J; Liu H Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373 [TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480 [TBL] [Abstract][Full Text] [Related]
13. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447 [TBL] [Abstract][Full Text] [Related]
14. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005 [TBL] [Abstract][Full Text] [Related]
15. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175 [TBL] [Abstract][Full Text] [Related]
16. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210 [TBL] [Abstract][Full Text] [Related]
17. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports. Xu J; Ming X; Wang C; Xu B; Xiao Y Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974 [TBL] [Abstract][Full Text] [Related]
18. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477 [TBL] [Abstract][Full Text] [Related]
19. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Feng D; Sun J Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019 [TBL] [Abstract][Full Text] [Related]
20. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis. Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]